Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols.
Nat Cancer
; 5(5): 742-759, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38429414
ABSTRACT
Successful immunotherapy relies on triggering complex responses involving T cell dynamics in tumors and the periphery. Characterizing these responses remains challenging using static human single-cell atlases or mouse models. To address this, we developed a framework for in vivo tracking of tumor-specific CD8+ T cells over time and at single-cell resolution. Our tools facilitate the modeling of gene program dynamics in the tumor microenvironment (TME) and the tumor-draining lymph node (tdLN). Using this approach, we characterize two modes of anti-programmed cell death protein 1 (PD-1) activity, decoupling induced differentiation of tumor-specific activated precursor cells from conventional type 1 dendritic cell (cDC1)-dependent proliferation and recruitment to the TME. We demonstrate that combining anti-PD-1 therapy with anti-4-1BB agonist enhances the recruitment and proliferation of activated precursors, resulting in tumor control. These data suggest that effective response to anti-PD-1 therapy is dependent on sufficient influx of activated precursor CD8+ cells to the TME and highlight the importance of understanding system-level dynamics in optimizing immunotherapies.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Linfocitos T CD8-positivos
/
Microambiente Tumoral
/
Inmunoterapia
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Nat Cancer
Año:
2024
Tipo del documento:
Article
País de afiliación:
Israel